The hospital burden of disease associated with bone metastases and skeletal-related events in patients with breast cancer, lung cancer, or prostate cancer in Spain

被引:99
作者
Pockett, R. D. [1 ]
Castellano, D. [2 ]
McEwan, P. [1 ]
Oglesby, A. [3 ]
Barber, B. L. [3 ]
Chung, K. [3 ]
机构
[1] Cardiff Res Consortium, MediCtr, Cardiff CF14 4UJ, S Glam, Wales
[2] Hosp Univ 12 Octubre, Med Oncol Serv, Madrid, Spain
[3] Amgen Inc, Global Hlth Econ, Thousand Oaks, CA 91320 USA
关键词
breast cancer; lung cancer; prostate cancer; metastases; skeletal-related events; burden of disease; QUALITY-OF-LIFE; ZOLEDRONIC ACID; SURVIVAL;
D O I
10.1111/j.1365-2354.2009.01135.x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Metastatic bone disease (MBD) is the most common cause of cancer pain and of serious skeletal-related events (SREs) reducing quality of life. Management of MBD involves a multimodal approach aimed at delaying the first SRE and reducing subsequent SREs. The objective of the study was to characterise the hospital burden of disease associated with MBD and SREs following breast, lung and prostate cancer in Spain. Patients admitted into a participating hospital, between 1 January 2003 and 31 December 2003, with one of the required cancers were identified and selected for inclusion into the study. The index admission to hospital, incidence of patients admitted and hospital length of stay were analysed. There were 28 162 patients identified with breast, lung and prostate cancer. The 3 year incidence rates of hospital admission due to MBD were 95 per 1000 for breast cancer, 156 per 1000 for lung cancer and 163 per 1000 for prostate cancer. For patients admitted following an SRE, the incidence rates were 211 per 1000 for breast cancer, 260 per 1000 for lung cancer and 150 per 1000 for prostate cancer. This study has shown that cancer patients consume progressively more hospital resources as MBD and subsequent SREs develop.
引用
收藏
页码:755 / 760
页数:6
相关论文
共 23 条
[1]  
[Anonymous], IARC CANCERBASE
[2]  
Berrino F., 2003, Annals of Oncology, V14, P9
[3]   Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy [J].
Clemons, Mark J. ;
Dranitsaris, George ;
Ooi, Wei S. ;
Yogendran, Geetha ;
Sukovic, Tatjana ;
Wong, Betty Y. L. ;
Verma, Sunil ;
Pritchard, Kathleen I. ;
Trudeau, Maureen ;
Cole, David E. C. .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (30) :4895-4900
[4]   THE CLINICAL COURSE OF BONE METASTASES FROM BREAST-CANCER [J].
COLEMAN, RE ;
RUBENS, RD .
BRITISH JOURNAL OF CANCER, 1987, 55 (01) :61-66
[5]   The role of bisphosphonates in breast cancer [J].
Coleman, RE .
BREAST, 2004, 13 :S19-S28
[6]   The role of zoledronic acid in cancer: Clinical studies in the treatment and prevention of bone metastases [J].
Coleman, RE ;
Seaman, JJ .
SEMINARS IN ONCOLOGY, 2001, 28 (02) :11-16
[7]   Metastatic bone disease: clinical features, pathophysiology and treatment strategies [J].
Coleman, RE .
CANCER TREATMENT REVIEWS, 2001, 27 (03) :165-176
[8]  
Delea Thomas, 2006, J Support Oncol, V4, P341
[9]   Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer [J].
DePuy, Venita ;
Anstrom, Kevin J. ;
Castel, Liana D. ;
Schulman, Kevin A. ;
Weinfurt, Kevin P. ;
Saad, Fred .
SUPPORTIVE CARE IN CANCER, 2007, 15 (07) :869-876
[10]   Cancer survival in European adolescents and young adults [J].
Gatta, G ;
Capocaccia, R ;
De Angelis, R ;
Stiller, C ;
Coebergh, JW .
EUROPEAN JOURNAL OF CANCER, 2003, 39 (18) :2600-2610